Curated News
By: NewsRamp Editorial Staff
May 17, 2024
Arecor Therapeutics Reports Strong 2023 Results and Outlines Expanding Product Pipeline
Discuss on Reddit
Substack
GithubTLDR
- Arecor's significant growth and new technology partnerships offer a competitive advantage in the diabetes and obesity market.
- Arestat technology and AT278 insulin aim to provide better glucose control for type 2 diabetics with high BMI, supported by Tetris Pharma's strong product sales.
- Arecor's focus on diabetes and obesity, along with technology partnerships, aims to improve the lives of patients and reduce hospital visits for brittle diabetes.
- Arecor's rapid-acting insulin and technology partnerships offer innovative solutions for diabetes and obesity care, with strong sales growth under new leadership.
Impact - Why it Matters
The news is important for investors and individuals interested in the pharmaceutical industry. Arecor Therapeutics' performance and future plans indicate growth and innovation in diabetes and obesity treatments, as well as potential for future licensing and market development. This could impact the availability of advanced insulin products and improved glucose control for type 2 diabetics with high BMI, as well as reducing hospital visits for patients with brittle diabetes.
Summary
Arecor Therapeutics PLC CEO Sarah Howell discusses the company's 2023 performance and future plans with Proactive's Stephen Gunnion. Arecor has seen significant growth, particularly with the launch of products incorporating its Arestat technology under a global licensing agreement, generating royalties. The company focuses on diabetes and obesity, with clinical results for their proprietary product, AT278, expected soon. Tetris Pharma, a subsidiary, has shown strong growth under new leadership, with product sales tripling to £2.9 million in 2023. Howell also noted the importance of technology partnerships and licensing programs, with Arecor entering into three active license programs and progressing well with its partners.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Arecor Therapeutics Reports Strong 2023 Results and Outlines Expanding Product Pipeline
